Skip to main content
    N

    Neurocrine Biosciences Inc (NBIX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $165.31
    -2.09 (-1.25%)

    Market Cap: $16.94B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Neurocrine Biosciences Inc (NBIX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 2, 2026. Financial statements from company filings, amounts in US dollars.

    Neurocrine Biosciences reported revenue of $2.86B for the fiscal year ended Dec 31, 2025, up 21.4% from the year before. That year, net income was $478.60M with a net margin of 16.7%, operating cash flow was $782.70M and free cash flow was $748.70M. The quarter ended Sep 30, 2026 had revenue of $1.12B and net income of $206.50M.

    Revenue and Margins

    The operating margin was 21.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $15.00M, a compound annual rate of 79.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.86B+21.4%98.2%21.6%16.7%
    Dec 2024$2.36B+24.8%98.6%24.2%14.5%
    Dec 2023$1.89B+26.8%97.9%13.3%13.2%
    Dec 2022$1.49B+31.3%98.4%16.7%10.4%
    Dec 2021$1.13B+8.4%98.7%9.0%7.9%
    Dec 2020$1.05B+32.7%99.0%15.6%38.9%
    Dec 2019$788.10M+74.7%99.1%9.2%4.7%
    Dec 2018$451.20M+179.2%98.9%8.2%4.7%
    Dec 2017$161.63M+977.5%99.2%-81.3%-88.2%
    Dec 2016$15.00MN/A100.0%-982.5%-940.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 40.2% from the year before. In the quarter ended Sep 2026, net income fell 1.4% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.86B$2.36B$1.89B$1.49B$1.13B$1.05B$788.10M$451.20M$161.63M$15.00M
    Cost of revenue$52.10M$34.00M$39.70M$23.20M$14.30M$10.10M$7.40M$4.90M$1.25M$0
    Gross profit$2.81B$2.32B$1.85B$1.47B$1.12B$1.04B$780.70M$446.30M$160.37M$15.00M
    Research and development$1.03B$743.60M$708.90M$463.80M$433.40M$439.50M$354.30M$160.60M$121.83M$94.29M
    Operating income$619.10M$570.50M$250.90M$249.00M$102.50M$163.00M$72.30M$36.80M-$131.36M-$147.37M
    Net income$478.60M$341.30M$249.70M$154.50M$89.60M$407.30M$37.00M$21.10M-$142.54M-$141.09M
    EBITDA$632.50MN/A$282.30M$299.10M$159.00M$175.30M$87.00M$59.70M-$115.42M-$142.40M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.12B$959.00M$814.50M$805.50M$794.90M$687.50M$572.60M$627.70M$622.10M$590.20M$515.30M$515.20M
    Gross profit$1.12B$959.00M$800.70M$787.90M$794.90M$677.20M$563.40M$618.40M$614.10M$581.00M$507.80M$506.70M
    Operating income$331.30M$151.50M$193.40M$210.90M$239.00M$145.60M$23.60M$142.00M$183.80M$145.40M$99.30M$150.30M
    Net income$206.50M$144.40M$197.90M$153.70M$209.50M$107.50M$7.90M$103.10M$129.80M$65.00M$43.40M$147.70M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $713.00M were 15.4% of total assets of $4.63B, against total liabilities of $1.38B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$4.63B$3.72B$3.25B$2.37B$2.07B$1.73B$1.31B$993.15M$817.59M$365.09M
    Current assets$2.52B$1.72B$1.61B$1.45B$972.80M$1.02B$831.00M$737.78M$554.92M$310.44M
    Cash and equivalents$713.00M$233.00M$251.10M$262.90M$340.80M$187.10M$112.30M$141.71M$254.71M$83.27M
    Total liabilities$1.38B$1.13B$1.02B$660.90M$698.50M$608.50M$669.10M$512.39M$445.45M$50.21M
    Short-term debtN/AN/A$170.10M$169.40M$0$10.30M$408.80M$62.34M$38.37M$14.86M
    Long-term debtN/AN/AN/AN/A$335.10M$317.90M$0$388.50M$369.62M$0
    Shareholder equity$3.25B$2.59B$2.23B$1.71B$1.37B$1.13B$636.90M$480.76M$372.14M$314.88M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$5.63B$5.36B$4.91B$4.63B$4.27B$3.89B$3.69B$3.72B$3.54B$3.31B$3.47B$3.25B
    Total liabilities$1.75B$1.67B$1.50B$1.38B$1.26B$1.20B$1.15B$1.13B$816.10M$795.80M$1.09B$1.02B
    Cash and equivalents$641.50M$332.40M$266.50M$713.00M$340.20M$264.00M$194.10M$233.00M$349.10M$139.70M$396.30M$251.10M
    Shareholder equity$3.88B$3.69B$3.41B$3.25B$3.00B$2.69B$2.54B$2.59B$2.72B$2.51B$2.39B$2.23B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 95.7% of operating cash flow. Share repurchases came to 22.4% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$782.70M$595.40M$389.90M$339.40M$256.50M$228.50M$147.00M$101.40M-$94.33M-$106.18M
    Capital expenditures$34.00M$38.20M$28.30M$16.50M$23.40M$10.90M$14.70M$24.80M$6.94M$4.11M
    Free cash flow$748.70M$557.20M$361.60M$322.90M$233.10M$217.60M$132.30M$76.60M-$101.27M-$110.29M
    Share repurchases$167.70M$300.00M$0$0N/AN/AN/AN/AN/AN/A
    Investing cash flow-$264.40M-$126.80M-$467.10M-$177.10M-$130.20M$4.10M-$211.10M-$242.90M-$251.25M$112.95M
    Financing cash flow-$38.30M-$486.70M$65.30M-$234.30M$27.40M-$157.80M$32.40M$29.50M$516.65M$2.39M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$395.20M$136.40M$145.80M$388.40M$227.50M$102.00M$64.80M$242.50M$158.00M$64.60M$130.30M$123.50M
    Capital expenditures$11.60M$7.80M$9.10M$2.40M$13.20M$12.50M$10.70M$7.30M$8.10M$11.60M$11.20M$5.40M
    Free cash flow$383.60M$128.60M$136.70M$386.00M$214.30M$89.50M$54.10M$235.20M$149.90M$53.00M$119.10M$118.10M
    Last 12 quarters

    Frequently Asked Questions About NBIX

    What is Neurocrine Biosciences' annual revenue?

    Neurocrine Biosciences reported revenue of $2.86B for the fiscal year ended Dec 31, 2025.

    How fast is Neurocrine Biosciences' revenue growing?

    Revenue was up 21.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 24.3%.

    Is Neurocrine Biosciences profitable?

    Yes. Neurocrine Biosciences reported net income of $478.60M for the fiscal year ended Dec 31, 2025, with a net margin of 16.7%.

    How much free cash flow does NBIX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $782.70M minus capital expenditures of $34.00M produced free cash flow of $748.70M.

    How much debt does Neurocrine Biosciences have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $713.00M.